|
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ENSG00000121671 |
Summary for CRY2 |
Gene summary |
| Gene information | Ensembl ID | ENSG00000121671 | Gene symbol | CRY2 |
| Gene name | cryptochrome circadian regulator 2 | |
| HGNC | 2385 | |
| Entrez ID | 1408 | |
| Gene type | protein_coding | |
| Synonyms | CRY2| | |
| UniProtAcc | Q49AN0 |
Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for CRY2 |
AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure.∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
Landscape of gene expressions across multiple cancer types. |
Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CRY2 | 2.26e+03 | -1.67e+00 | 1.97e-01 | -8.48e+00 | 2.23e-17 | 2.93e-14 | ESCA |
| CRY2 | 2.95e+03 | -1.67e+00 | 3.96e-01 | -4.22e+00 | 2.49e-05 | 1.28e-04 | CHOL |
Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CRY2 | 3.26e+03 | -1.20e+00 | 6.22e-02 | -1.93e+01 | 2.83e-83 | 7.29e-82 | BRCA |
Top |
Sex-biased somatic mutation for CRY2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for CRY2 |
Landscape of DNA methylation across multiple cancer types. |
Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg15812322 | chr11:45846847 | CGI:chr11:45847191-45847862 | promoter | 5.43e-01 | 6.81e-01 | -2.01e+00 | 4.45e-02 | 4.78e-02 | -1.38e-01 |
| ACC | cg15812322 | chr11:45846847 | CGI:chr11:45847191-45847862 | promoter | 6.97e-01 | 8.38e-01 | -2.53e+00 | 1.14e-02 | 2.73e-02 | -1.42e-01 |
| KICH | cg15812322 | chr11:45846847 | CGI:chr11:45847191-45847862 | promoter | 7.66e-01 | 6.25e-01 | 3.09e+00 | 1.98e-03 | 9.24e-03 | 1.41e-01 |
| KICH | cg07326765 | chr11:45846898 | CGI:chr11:45847191-45847862 | promoter | 8.56e-01 | 7.47e-01 | 2.14e+00 | 3.22e-02 | 4.37e-02 | 1.09e-01 |
Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| HNSC | cg07326765 | chr11:45846898 | CGI:chr11:45847191-45847862 | promoter | 5.48e-01 | 7.03e-01 | -2.65e+00 | 8.15e-03 | 1.08e-02 | -1.55e-01 |
| LUSC | cg24354272 | chr11:45846479 | CGI:chr11:45847191-45847862 | promoter | 6.24e-01 | 8.94e-01 | -4.33e+00 | 1.47e-05 | 5.26e-04 | -2.70e-01 |
| LUSC | cg15812322 | chr11:45846847 | CGI:chr11:45847191-45847862 | promoter | 3.08e-01 | 6.55e-01 | -4.07e+00 | 4.71e-05 | 5.50e-04 | -3.47e-01 |
| LUSC | cg07326765 | chr11:45846898 | CGI:chr11:45847191-45847862 | promoter | 4.00e-01 | 6.99e-01 | -3.13e+00 | 1.73e-03 | 3.78e-03 | -2.99e-01 |
| LUSC | cg16006220 | chr11:45846944 | CGI:chr11:45847191-45847862 | promoter | 2.05e-01 | 3.40e-01 | -3.05e+00 | 2.31e-03 | 4.62e-03 | -1.35e-01 |
| LUSC | cg07524456 | chr11:45846950 | CGI:chr11:45847191-45847862 | promoter | 1.62e-01 | 2.73e-01 | -3.24e+00 | 1.21e-03 | 2.96e-03 | -1.11e-01 |
| BLCA | cg24354272 | chr11:45846479 | CGI:chr11:45847191-45847862 | promoter | 6.52e-01 | 8.83e-01 | -4.07e+00 | 4.78e-05 | 2.40e-04 | -2.31e-01 |
| BLCA | cg15812322 | chr11:45846847 | CGI:chr11:45847191-45847862 | promoter | 4.00e-01 | 5.79e-01 | -3.07e+00 | 2.16e-03 | 4.16e-03 | -1.79e-01 |
| ESCA | cg15812322 | chr11:45846847 | CGI:chr11:45847191-45847862 | promoter | 4.28e-01 | 6.47e-01 | -2.50e+00 | 1.24e-02 | 3.71e-02 | -2.20e-01 |
| ESCA | cg07326765 | chr11:45846898 | CGI:chr11:45847191-45847862 | promoter | 5.44e-01 | 7.81e-01 | -2.88e+00 | 3.99e-03 | 3.39e-02 | -2.37e-01 |
| CHOL | cg24354272 | chr11:45846479 | CGI:chr11:45847191-45847862 | promoter | 8.15e-01 | 5.89e-01 | 3.46e+00 | 5.30e-04 | 8.63e-03 | 2.26e-01 |
| CHOL | cg16006220 | chr11:45846944 | CGI:chr11:45847191-45847862 | promoter | 3.77e-01 | 2.01e-01 | 2.65e+00 | 7.96e-03 | 1.92e-02 | 1.76e-01 |
Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg15812322 | chr11:45846847 | CGI:chr11:45847191-45847862 | promoter | 5.43e-01 | 4.20e-01 | 6.90e+00 | 5.27e-12 | 1.53e-11 | 1.23e-01 |
| BRCA | cg07326765 | chr11:45846898 | CGI:chr11:45847191-45847862 | promoter | 6.61e-01 | 5.09e-01 | 6.94e+00 | 3.89e-12 | 1.14e-11 | 1.52e-01 |
| BRCA | cg16006220 | chr11:45846944 | CGI:chr11:45847191-45847862 | promoter | 3.91e-01 | 2.03e-01 | 2.98e+00 | 2.89e-03 | 3.55e-03 | 1.88e-01 |
| BRCA | cg07524456 | chr11:45846950 | CGI:chr11:45847191-45847862 | promoter | 3.17e-01 | 1.54e-01 | 8.96e+00 | 3.12e-19 | 1.58e-18 | 1.63e-01 |
| THCA | cg16006220 | chr11:45846944 | CGI:chr11:45847191-45847862 | promoter | 4.93e-01 | 3.90e-01 | 2.82e+00 | 4.85e-03 | 8.02e-03 | 1.02e-01 |
| COAD | cg07524456 | chr11:45846950 | CGI:chr11:45847191-45847862 | promoter | 2.47e-01 | 1.46e-01 | 2.29e+00 | 2.21e-02 | 2.79e-02 | 1.00e-01 |
| LIHC | cg24354272 | chr11:45846479 | CGI:chr11:45847191-45847862 | promoter | 7.36e-01 | 5.46e-01 | 4.07e+00 | 4.67e-05 | 2.16e-04 | 1.90e-01 |
| KIRP | cg07326765 | chr11:45846898 | CGI:chr11:45847191-45847862 | promoter | 7.97e-01 | 6.94e-01 | 2.93e+00 | 3.41e-03 | 8.33e-03 | 1.03e-01 |
Top |
Exon skipping events with PSI in TCGA for CRY2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
Landscape of exon skipping events across multiple cancer types. |
Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for CRY2 |
| ∗Please access CAeditome for RNA editing annotation. |
Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for CRY2 |
TFs related to CRY2.∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
CRY2 related gene.∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for CRY2 |
RBPs related to ES in CRY2.∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | CNOT4 | exon_skip_58583 | 1.07e+01 | 9.82e-01 | 1.02e+01 | 1.64e-02 | Male-biased |
| READ | CNOT4 | exon_skip_58583 | 1.02e+01 | 2.69e-03 | 1.07e+01 | 9.96e-01 | Female-biased |
CRY2 related ES.∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs6485613 | chr11:45315889:C:T | - | -0.0925435773444561 | 0.0477761855369545 | SARC | Female-baised eQTL |
| rs6485615 | chr11:45316102:T:C | - | -0.0925435773444561 | 0.0477761855369545 | SARC | Female-baised eQTL |
| rs7480542 | chr11:45317076:G:A | - | -0.0925435773444561 | 0.0477761855369545 | SARC | Female-baised eQTL |
| rs4755963 | chr11:45317446:C:T | - | -0.0925435773444561 | 0.0477761855369545 | SARC | Female-baised eQTL |
| rs4755314 | chr11:45317447:G:A | - | -0.0925435773444561 | 0.0477761855369545 | SARC | Female-baised eQTL |
Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs61882911 | chr11:45570381:C:T | - | 0.0742702412985674 | 0.000535550960688952 | STAD | Male-baised eQTL |
| rs10838528 | chr11:45896403:A:C | - | -0.101765996326627 | 0.000738375809245267 | STAD | Male-baised eQTL |
| rs4755329 | chr11:45574516:C:G | - | 0.0656667856854381 | 0.00339887788411618 | STAD | Male-baised eQTL |
| rs55889419 | chr11:45563701:C:T | - | 0.0646137010342656 | 0.00369196301218412 | STAD | Male-baised eQTL |
| rs2946006 | chr11:45983506:T:A | - | -0.0707616534300591 | 0.0131821331973129 | STAD | Male-baised eQTL |
| rs11038514 | chr11:45526713:T:C | - | 0.0659969904267377 | 0.0137848521562207 | STAD | Male-baised eQTL |
| rs57591833 | chr11:45592862:G:A | - | 0.0548765071883389 | 0.0139108980779026 | STAD | Male-baised eQTL |
| rs11038519 | chr11:45532433:C:T | - | 0.06568860666329 | 0.0146130243134415 | STAD | Male-baised eQTL |
| rs6485632 | chr11:45545296:G:A | - | -0.0494950357168566 | 0.0309505085176118 | STAD | Male-baised eQTL |
| rs7131249 | chr11:45545573:G:A | - | -0.0494950357168566 | 0.0309505085176118 | STAD | Male-baised eQTL |
| rs4755328 | chr11:45552864:G:T | - | 0.0518405598996273 | 0.0426720783619053 | STAD | Male-baised eQTL |
| rs1488674 | chr11:45552247:A:C | - | -0.0482655464642293 | 0.0455793346224556 | STAD | Male-baised eQTL |
| rs7396878 | chr11:45601248:T:C | - | -0.0581834612049056 | 0.0451632089107165 | KIRC | Male-baised eQTL |
| rs56168061 | chr11:43680980:A:G | - | 0.0612890090766741 | 0.046752477440627 | KIRC | Male-baised eQTL |
| rs421350 | chr11:36388872:T:G | - | -0.0719744088045268 | 0.0287980591390285 | BLCA | Male-baised eQTL |
| rs606442 | chr11:36388276:T:C | - | -0.0681737762180555 | 0.0367423954086883 | BLCA | Male-baised eQTL |
| rs73458310 | chr11:44979492:A:G | - | 0.075598076893188 | 0.0226845102014968 | COAD | Male-baised eQTL |
| rs73458312 | chr11:44979664:G:A | - | 0.075598076893188 | 0.0226845102014968 | COAD | Male-baised eQTL |
| rs12291023 | chr11:44979819:G:T | - | 0.075598076893188 | 0.0226845102014968 | COAD | Male-baised eQTL |
| rs7107225 | chr11:44985190:A:G | - | 0.0715297842756828 | 0.0273309583761277 | COAD | Male-baised eQTL |
| rs2170906 | chr11:44981810:G:C | - | 0.0722715749776373 | 0.031890708796062 | COAD | Male-baised eQTL |
| rs11038242 | chr11:44981915:C:T | - | 0.0722715749776373 | 0.031890708796062 | COAD | Male-baised eQTL |
| rs7108720 | chr11:44982695:C:T | - | 0.0722715749776373 | 0.031890708796062 | COAD | Male-baised eQTL |
| rs7109107 | chr11:44982838:G:C | - | 0.0722715749776373 | 0.031890708796062 | COAD | Male-baised eQTL |
| rs78754302 | chr11:44982876:T:C | - | 0.0722715749776373 | 0.031890708796062 | COAD | Male-baised eQTL |
| rs7128096 | chr11:44982919:T:A | - | 0.0722715749776373 | 0.031890708796062 | COAD | Male-baised eQTL |
| rs12270372 | chr11:44983056:G:C | - | 0.0722715749776373 | 0.031890708796062 | COAD | Male-baised eQTL |
| rs78192239 | chr11:44983068:A:G | - | 0.0722715749776373 | 0.031890708796062 | COAD | Male-baised eQTL |
| rs12270424 | chr11:44983117:G:C | - | 0.0722715749776373 | 0.031890708796062 | COAD | Male-baised eQTL |
| rs117425244 | chr11:44983119:A:T | - | 0.0722715749776373 | 0.031890708796062 | COAD | Male-baised eQTL |
| rs12270498 | chr11:44983280:G:A | - | 0.0722715749776373 | 0.031890708796062 | COAD | Male-baised eQTL |
| rs11038246 | chr11:44984568:G:C | - | 0.0722715749776373 | 0.031890708796062 | COAD | Male-baised eQTL |
| rs74472562 | chr11:44741205:C:T | - | 0.0791477117067476 | 0.0481866560803531 | COAD | Male-baised eQTL |
Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg24305156 | chr11:45850385 | gene,enhancer | -0.352900583599448 | 3.65555008880939e-05 | -0.3570457873608211 | 1.9615541008090256e-07 | KIRP |
Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg07326765 | chr11:45846898 | promoter | -0.334314199977143 | 2.25933246921051e-06 | -0.640075651121942 | 2.137213925480624e-10 | PAAD |
Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of CRY2 |
Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000121671 | CRY2 | C0005586 | Bipolar Disorder | 4 | PSYGENET |
| ENSG00000121671 | CRY2 | C0011570 | Mental Depression | 3 | PSYGENET |
| ENSG00000121671 | CRY2 | C0011581 | Depressive disorder | 4 | PSYGENET |
| ENSG00000121671 | CRY2 | C0023473 | Myeloid Leukemia, Chronic | 1 | CTD_human |
| ENSG00000121671 | CRY2 | C0085159 | Seasonal Affective Disorder | 1 | PSYGENET |